XPhyto Secures Exclusive Psychedelic Drug Development Agreement
The Pharma Data
NOVEMBER 9, 2020
On August 20, 2018, the Company signed the Exclusive Dealing Agreement with Prof. He is also a current member of the Health Canada Scientific Advisory Committee on Pharmaceutical Sciences and Clinical Pharmacology and the Scientific Advisory Panel on Opioid Analgesic Abuse. XPhyto Therapeutics Corp. ON BEHALF OF THE BOARD.
Let's personalize your content